Previous 10 | Next 10 |
Datato be Presented on Ongoing Natesto Spermatogenesis Study, Study Evaluating theEffect of Natesto Nasal Testosterone on Male Fertility Parameters ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercia...
TrovaGene (NASDAQ: TROV ) +121% . More news on: TrovaGene, Inc., Seelos Therapeutics Inc, Tonix Pharmaceuticals Holding Corp., Stocks on the move, Read more ...
Aytu Assumes Milestone & Royalty-Based Licensing Agreement with SUDA Pharmaceuticals to Sublicense ZolpiMist Outside of the United States and Canada ENGLEWOOD, CO / ACCESSWIRE / March 6, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on comme...
Gainers: Bio-Path Holdings (NASDAQ: BPTH ) +180% . Renren (NYSE: RENN ) +47% . Seelos Therapeutics (NASDAQ: SEEL ) +28% . Abercrombie & Fitch (NYSE: ANF ) +24% . Aytu BioScience (NASDAQ: AYTU ) +24% . OHR Pharmaceutical (NASDAQ: OHRP ) +23% . Proteon Therapeutics (NASDAQ: P...
Thinly traded nano cap Aytu BioScience ( AYTU +43.6% ) is up on a whopping 44x surge in volume in response to its in-licensing partnership with SUDA Pharmaceuticals for the distribution of sleep aid ZolpiMist (zolpidem tartrate oral spray) outside of the U.S. and Canada (Sanofi mark...
Bio-Path Holdings (NASDAQ: BPTH ) +55% on positive prexigebersen data. More news on: Bio-Path Holdings, Inc., Abercrombie & Fitch, China Automotive Systems, Inc., Stocks on the move, Read more ...
Aytu Assumes Milestone & Royalty-Based Licensing Agreement with SUDA Pharmaceuticals to Sublicense ZolpiMist Outside of the United States and Canada ENGLEWOOD, CO / ACCESSWIRE / March 6, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on comme...
Aytu BioScience ( AYTU -11% ) is down on more than double normal volume, albeit up 13% from the intraday low of $1.01, following its fiscal Q2 results . Highlights: More news on: Aytu BioScience, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move,...
Aytu BioScience, Inc. (AYTU) Q2 2019 Earnings Conference Call February 7, 2019 9:00 AM ET Company Participants Josh Disbrow - Chief Executive Officer Dave Green - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Carl Byrnes - Northland...
Solid Biosciences (NASDAQ: SLDB ) -72% on disappointing DMD gene therapy data. More news on: Solid Biosciences, Inc., USA Technologies, Inc., Avadel Pharmaceuticals plc, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...